Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic with reduced versus standard tacrolimus after de novo renal transplantation
2005-001518-42Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate sodium, tacrolimus and basiliximab in kidney transplant (2 arms), sponsored by Novartis. Primary endpoint: Renal function at 6 months. Started Jun 2005; status: completed.
02
Drugs
mycophenolate sodiumtacrolimusbasiliximab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2005-001518-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001518-42.